Psychopharmacological advances in eating disorders

References

• Eddy KT, Tabri N, Thomas JJ, et al. Recovery from anorexia nervosa and bulimia nervosa at 22-year follow-Up. J Clin Psychiatry. 2017;78:184–189.
   PubMed Web of Science ®Google Scholar
• Delay J, Deniker P Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. J Clin Exp Psychopathol. 1955;16:104–112.
   PubMedGoogle Scholar
• Thuillier J. Les dix ans qui ont changé la folie. Paris: Robert Laffont; 1980.
   Google Scholar
• Kuhn R The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry. 1958;115:459–464.
   PubMed Web of Science ®Google Scholar
• Steinberg H, Himmerich H Roland Kuhn-100th birthday of an innovator of clinical psychopharmacology. Psychopharmacol Bull. 2012;45:48–50.
   PubMedGoogle Scholar
• Yellowlees AJ Anorexia and bulimia in anorexia nervosa: a study of psychosocial functioning and associated psychiatric symptomatology. Br J Psychiatry. 1985;146:648–652.
   PubMed Web of Science ®Google Scholar
• Johnson C, Stuckey M, Mitchell J Psychopharmacological treatment of anorexia nervosa and bulimia. J Nerv Ment Dis 1983;171:524–534.
   PubMed Web of Science ®Google Scholar
• Miniati M, Mauri M, Ciberti A, et al. Psychopharmacological options for adult patients with anorexia nervosa. CNS Spectr. 2016;21:134–142.
   PubMed Web of Science ®Google Scholar
• Vandereycken W Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride. Br J Psychiatry. 1984;144:288–292.
   PubMed Web of Science ®Google Scholar
• Biederman J, Herzog DB, Rivinus TM, et al. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1985;5:10–16.
   PubMed Web of Science ®Google Scholar
• Halmi KA, Eckert E, LaDu TJ, et al. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Review and synthesis. J Nerv Ment Dis. 1983;171:524–534.
   PubMed Web of Science ®Google Scholar
• Greetfeld M, Cuntz U, Voderholzer U Pharmacotherapy for anorexia nervosa and bulimia nervosa. Fortschr Neurol Psychiatr. 2012;80:9–16.
   PubMed Web of Science ®Google Scholar
• White JH, Schnaultz NL Successful treatment of anorexia nervosa with imipramine. Dis Nerv Syst. 1977;38:567–568.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic diagnostic and statistical manual of mental disorders and statistical manual of mental disorders. (3rd ed.). Washington (DC): APA Publishing; 1980.
   Google Scholar
• Russell G Bulimia nervosa: an ominous variant of anorexia nervosa. Psychol Med. 1979;9:429–448.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington (VA): APA Publishing; 2013.
   Google Scholar
• Freeman CPL, Hampson M. Fluoxetine as a treatment for bulimia nervosa. Int J Obes 1987:1 Suppl 3: 163–170.
   Google Scholar
• Beumont PJ, Russell JD, Touyz SW, et al. Intensive nutritional counselling in bulimia nervosa: a role for supplementation with fluoxetine? Aust N Z J Psychiatry. 1997;31:514–524.
   PubMed Web of Science ®Google Scholar
• Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry. 1992;49:139–147.
   PubMed Web of Science ®Google Scholar
• Goldstein D, Wilson M, Thompson V, et al. Long-term fluoxetine treatment of bulimia nervosa. Br J Psychiatry. 1995;166:660–666.
   PubMed Web of Science ®Google Scholar
• Kanerva R, Rissanen A, Sarna S Fluoxetine in the treatment of anxiety, depressive symptoms, and eating-related symptoms in bulimia nervosa. Nord J Psychiatry. 1994;49:237–242.
   Web of Science ®Google Scholar
• Romano S, Halmi K, Sarkar N, et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry. 2002;159:96–102.
   PubMed Web of Science ®Google Scholar
• Aigner M, Treasure J, Kaye W, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry. 2011;12:400–443.
   PubMed Web of Science ®Google Scholar
• Bacaltchuk J, Hay P Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev. 2003;4:CD003391.
   PubMedGoogle Scholar
• Bacaltchuk J, Hay P, Trefiglio R Antidepressants versus psychological treatments and their combination for bulimia nervosa. Cochrane Database Syst Rev. 2001;4:CD003385.
   PubMedGoogle Scholar
• Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41:2177–2182.
   PubMed Web of Science ®Google Scholar
• Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21:207–212.
   PubMed Web of Science ®Google Scholar
• Davis H, Attia E. Pharmacotherapy of eating disorders. Curr Opin Psychiatry. 2017;30:452–457.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Au K, Dornik J, et al. Olanzapine treatment for patients with anorexia nervosa. Can J Psychiatry. 2017;62:506–507.
   PubMed Web of Science ®Google Scholar
• Götestam KG, Eriksen L, Heggestad T, et al. Prevalence of eating disorders in Norwegian general hospitals 1990-1994: admissions per year and seasonality. Int J Eat Disord. 1998;23:57–64.
   PubMed Web of Science ®Google Scholar
• Keski-Rahkonen A, Mustelin L Epidemiology of eating disorders in Europe: prevalence, incidence, comorbidity, course, consequences, and risk factors. Curr Opin Psychiatry. 2016;29:340–345.
   PubMed Web of Science ®Google Scholar
• Javaras KN, Runfola CD, Thornton LM, et al. Sex- and age-specific incidence of healthcare-register-recorded eating disorders in the complete Swedish 1979-2001 birth cohort. Int J Eat Disord. 2015;48:1070–1081.
   PubMed Web of Science ®Google Scholar
• Kornstein SG Epidemiology and recognition of binge-eating disorder in psychiatry and primary care. J Clin Psychiatry. 2017;78 Suppl 1:3–8.
   PubMedGoogle Scholar
• Miniati M, Benvenuti A, Bologna E, et al. Mood spectrum comorbidity in patients with anorexia and bulimia nervosa. Eat Weight Disord. 2016. DOI: 10.1007/s40519-016-0333-1. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Koch SV, Larsen JT, Mouridsen SE, et al. Autism spectrum disorder in individuals with anorexia nervosa and in their first- and second-degree relatives: Danish nationwide register-based cohort-study. Br J Psychiatry. 2015;206:401–407.
   PubMed Web of Science ®Google Scholar
• Svedlund NE, Norring C, Ginsberg Y, et al. Symptoms of attention deficit hyperactivity disorder (ADHD) among adult eating disorder patients. BMC Psychiatry. 2017;17:19.
   PubMed Web of Science ®Google Scholar
• Nazar BP, Bernardes C, Peachey G, et al. The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Int J Eat Disord. 2016;49:1045–1057.
   PubMed Web of Science ®Google Scholar
• Ulfvebrand S, Birgegård A, Norring C, et al. Psychiatric comorbidity in women and men with eating disorders results from a large clinical database. Psychiatry Res. 2015;230:294–299.
   PubMed Web of Science ®Google Scholar
• Bulik CM, Sullivan PF, Tozzi F, et al. Prevalence, heritability, and prospective risk factors for anorexia nervosa. Arch Gen Psychiatry. 2006;63:305–312.
   PubMed Web of Science ®Google Scholar
• Lilenfeld L, Kaye W, Greeno C, et al. A controlled family study of restricting anorexia and bulimia nervosa: comorbidity in probands and disorders in first-degree relatives. Arch Gen Psychiatry. 1998;55:603–610.
   PubMed Web of Science ®Google Scholar
• Strober M, Freeman R, Lampert C, et al. Controlled family study of anorexia nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes. Am J Psychiatry. 2000;157:393–401.
   PubMed Web of Science ®Google Scholar
• Strober M, Freeman R, Lampert C, et al. Males with anorexia nervosa: a controlled study of eating disorders in first-degree relatives. Int J Eat Disord. 2001;29:263–269.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang H, Bloss CS, et al. A genome-wide association study on common SNPs and rare CNVs in anorexia nervosa. Mol Psychiatry. 2011;16:949–959.
   PubMed Web of Science ®Google Scholar
• Boraska V, Franklin CS, Floyd JA, et al. A genome-wide association study of anorexia nervosa. Mol Psychiatry 2014;19:1085–1094.
   PubMed Web of Science ®Google Scholar
• Duncan L, Yilmaz Z, Gaspar H, et al. Significant locus and metabolic genetic correlations revealed in genome-wide association study of anorexia nervosa. Am J Psychiatry. 2017;174:850–858.
   PubMed Web of Science ®Google Scholar
• Wade TD, Gordon S, Medland S, et al. Genetic variants associated with disordered eating. Int J Eat Disord. 2013;46:594–608.
   PubMed Web of Science ®Google Scholar
• Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47:1236–1241.
   PubMed Web of Science ®Google Scholar
• Nordsletten AE, Larsson H, Crowley JJ, et al. Patterns of nonrandom mating within and across 11 major psychiatric disorders. JAMA Psychiatry. 2016;73:354–361.
   PubMed Web of Science ®Google Scholar
• Micali N, Field AE, Treasure JL, et al. Are obesity risk genes associated with binge eating in adolescence? Obesity. 2015; 23:1729–1736.
   PubMed Web of Science ®Google Scholar
• Treasure J (2011). Neuroimaging of eating disorders: commentary. In: Shenton ME, Turetsky BI editors. Understanding neuropsychiatric disorders: insights from neuroimaging. Cambridge: Cambridge University Press. pp. 510–516.
   Google Scholar
• Marsh R, Horga G, Wang Z, et al. An FMRI study of self-regulatory control and conflict resolution in adolescents with bulimia nervosa. Am J Psychiatry. 2011;168:1210–1220.
   PubMed Web of Science ®Google Scholar
• Dohle S, Diel K, Hofmann W. Executive functions and the self-regulation of eating behavior: a review. Appetite. 2017. DOI: 10.1016/j.appet.2017.05.041. [Epub ahead of print]
   PubMedGoogle Scholar
• Witt AA, Lowe MR Hedonic hunger and binge eating among women with eating disorders. Int J Eat Disord. 2014;47:273–280.
   PubMed Web of Science ®Google Scholar
• Berridge KC, Ho CY, Richard JM, et al. The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res. 2010;1350:43–64.
   PubMed Web of Science ®Google Scholar
• Morton GJ, Meek TH, Schwartz MW Neurobiology of food intake in health and disease. Nat Rev Neurosci. 2014;15:367–378.
   PubMed Web of Science ®Google Scholar
• Hall KD, Hammond RA, Rahmandad H Dynamic interplay among homeostatic, hedonic, and cognitive feedback circuits regulating body weight. Am J Public Health. 2014;104:1169–1175.
   PubMed Web of Science ®Google Scholar
• Steiger H Eating disorders and the serotonin connection: state, trait and developmental effects. J Psychiatry Neurosci. 2004;29:20–29.
   PubMed Web of Science ®Google Scholar
• Meunier CN, Chameau P, Fossier PM Modulation of synaptic plasticity in the cortex needs to understand all the players. Front Synaptic Neurosci. 2017;9:2.
   PubMedGoogle Scholar
• Saper CB, Chou TC, Elmquist JK The need to feed: homeostatic and hedonic control of eating. Neuron. 2002;36:199–211.
   PubMed Web of Science ®Google Scholar
• Friederich HC, Kumari V, Uher R, et al. Differential motivational responses to food and pleasurable cues in anorexia and bulimia nervosa: a startle reflex paradigm. Psychol Med. 2006;36:1327–1335.
   PubMed Web of Science ®Google Scholar
• Kaye WH, Wierenga CE, Bailer UF, et al. Does a shared neurobiology for foods and drugs of abuse contribute to extremes of food ingestion in anorexia and bulimia nervosa? Biol Psychiatry. 2013;73:836–842.
   PubMed Web of Science ®Google Scholar
• Balodis IM, Grilo CM, Potenza MN Neurobiological features of binge eating disorder. CNS Spectrums. 2015;20:557–565.
   PubMed Web of Science ®Google Scholar
• Frank GK The perfect storm - a bio-psycho-social risk model for developing and maintaining eating disorders. Front Behav Neurosci. 2016;10:44.
   PubMed Web of Science ®Google Scholar
• Jappe LM, Frank GK, Shott ME, et al. Heightened sensitivity to reward and punishment in anorexia nervosa. Int J Eat Disord. 2011;44:317–324.
   PubMed Web of Science ®Google Scholar
• Avena NM, Bocarsly ME Dysregulation of brain reward systems in eating disorders: neurochemical information from animal models of binge eating, bulimia nervosa, and anorexia nervosa. Neuropharmacology. 2012;63:87–96.
   PubMed Web of Science ®Google Scholar
• Nathan PJ, Bullmore ET From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol. 2009;12:995–1008.
   PubMed Web of Science ®Google Scholar
• Yeomans MR, Gray RW Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev. 2002;26:713–728.
   PubMed Web of Science ®Google Scholar
• Olszewski PK, Alsiö J, Schiöth HB, et al. Opioids as facilitators of feeding: can any food be rewarding? Physiol Behav. 2011;104:105–110.
   PubMed Web of Science ®Google Scholar
• Drewnowski A, Krahn DD, Demitrack MA, et al. Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr. 1995;61:1206–1212.
   PubMed Web of Science ®Google Scholar
• Nathan PJ, O’Neill BV, Bush MA, et al. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist. J Clin Pharmacol. 2012;52:464–474.
   PubMed Web of Science ®Google Scholar
• Burger KS, Berner LA A functional neuroimaging review of obesity, appetitive hormones and ingestive behaviour. Physiol Behav. 2014;136:121–127.
   PubMed Web of Science ®Google Scholar
• Egecioglu E, Skibicka KP, Hansson C, et al. Hedonic and incentive signals for body weight control. Rev Endocr Metab Disord. 2011;12:141–151.
   PubMed Web of Science ®Google Scholar
• Roh E, Kim MS Brain regulation of energy metabolism. Endocrinol Metab. 2016;31:519–524.
   Google Scholar
• Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature. 2000;404:661–671.
   PubMed Web of Science ®Google Scholar
• Cummings D, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–1719.
   PubMed Web of Science ®Google Scholar
• Anderberg RH, Richard JE, Eerola K, et al. Glucagon-like peptide-1 and its analogues act in the dorsal raphe and modulate central serotonin to reduce appetite and body weight. Diabetes. 2017;66:1062–1073.
   PubMed Web of Science ®Google Scholar
• Kim SF, Huang AS, Snowman AM, et al. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA. 2007;104:3456–3459.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Minkwitz J, Kirkby KC Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets. 2015;15:252–260.
   PubMed Web of Science ®Google Scholar
• Harrold JA, Halford JC The hypothalamus and obesity. Recent Pat CNS Drug Discov. 2006;1:305–314.
   PubMedGoogle Scholar
• Xu Y, Wu Z, Sun H, et al. Glutamate mediates the function of melanocortin receptor 4 on Sim1 neurons in body weight regulation. Cell Metab. 2013;18:860–870.
   PubMed Web of Science ®Google Scholar
• Meister B, Gömüç B, Suarez E, et al. Hypothalamic proopiomelanocortin (POMC) neurons have a cholinergic phenotype. Eur J Neurosci. 2006;24:2731–2740.
   PubMed Web of Science ®Google Scholar
• Murray S, Tulloch A, Gold MS, et al. Hormonal and neural mechanisms of food reward, eating behaviour and obesity. Nat Rev Endocrinol. 2014;10:540–552.
   PubMed Web of Science ®Google Scholar
• Lockie SH, Andrews ZB The hormonal signature of energy deficit: increasing the value of food reward. Mol Metab. 2013;2:329–336.
   PubMed Web of Science ®Google Scholar
• Fernandes MF, Sharma S, Hryhorczuk C, et al. Nutritional controls of food reward. Can J Diabetes. 2013;37:260–268.
   PubMed Web of Science ®Google Scholar
• Bautista CJ, Martínez-Samayoa PM, Zambrano E Sex steroids regulation of appetitive behavior. Mini Rev Med Chem. 2012;12:1107–1118.
   PubMed Web of Science ®Google Scholar
• Cloak NL, Powers PS Beating obesity: help patients control binge eating disorder and night eating syndrome. Curr Psychiatr. 2006;5:17–28.
   Google Scholar
• Fairburn CG, Cooper Z, Doll HA, et al. The natural course of bulimia nervosa and binge eating disorder in young women. Arch Gen Psychiatry. 2000;37:659–665.
   Google Scholar
• Molinari E, Baruffi M, Croci M, et al. Binge eating disorder in obesity: comparison of different therapeutic strategies. Eat Weight Disord. 2005;10:154–161.
   PubMedGoogle Scholar
• Grissett NI, Fitzgibbon ML The clinical significance of binge eating in an obese population: support for BED and questions regarding its criteria. Addict Behav. 1996;21:57–66.
   PubMed Web of Science ®Google Scholar
• Gormally J, Black S, Daston S, et al. The assessment of binge eating severity among obese persons. Addict Behav. 1982;7:47–55.
   PubMed Web of Science ®Google Scholar
• De Zwaan M Binge eating disorder and obesity. Int J Obes Relat Metab Disord. 2001;25 Suppl 1:51–55.
   PubMed Web of Science ®Google Scholar
• Volkow ND, O’Brien CP Issues for DSM-V: should obesity be included as a brain disorder? Am J Psychiatry. 2007;164:708–710.
   PubMed Web of Science ®Google Scholar
• Schmidt U, Adan R, Böhm I, et al. Eating disorders: the big issue. Lancet Psychiatry. 2016;3:313–315.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Schönknecht P, Heitmann S, et al. Laboratory parameters and appetite regulators in patients with anorexia nervosa. J Psychiatr Pract. 2010;16:82–92.
   PubMed Web of Science ®Google Scholar
• Sachs KV, Harnke B, Mehler PS, et al. Cardiovascular complications of anorexia nervosa: a systematic review. Int J Eat Disord. 2016;49:238–248.
   PubMed Web of Science ®Google Scholar
• Zerwas S, Larsen JT, Petersen L, et al. The incidence of eating disorders in a Danish register study: associations with suicide risk and mortality. J Psychiatr Res. 2015;65:16–22.
   PubMed Web of Science ®Google Scholar
• Steinhausen HC The outcome of anorexia nervosa in the 20th century. Am J Psychiatry. 2002;159:1284–1293.
   PubMed Web of Science ®Google Scholar
• Alvarenga MS, Koritar P, Pisciolaro F, et al. Eating attitudes of anorexia nervosa, bulimia nervosa, binge eating disorder and obesity without eating disorder female patients: differences and similarities. Physiol Behav. 2014;131:99–104.
   PubMed Web of Science ®Google Scholar
• Hilbert A, Pike KM, Goldschmidt AB, et al. Risk factors across the eating disorders. Psychiatry Res. 2014;220:500–506.
   PubMed Web of Science ®Google Scholar
• Heatherton TF, Polivy J (1992). Chronic dieting and eating disorders: a spiral model. In: Crowther J, Hobfall SE, Stephens MAP, et al. editors. The etiology of bulimia: the individual and family context. Washington (DC): Hemisphere. pp. 133–155.
   Google Scholar
• Tozzi F, Thornton L, Klump K, et al. Symptom fluctuation in eating disorders: correlates of diagnostic crossover. Am J Psychiatry 2005;162:732–740.
   PubMed Web of Science ®Google Scholar
• Hay P, Fairburn C The validity of the DSM-IV scheme for classifying bulimic eating disorders. Int J Eat Disord. 1998;23:7–15.
   PubMed Web of Science ®Google Scholar
• Halabe Bucay A Donepezil (aricept) as a treatment for anorexia nervosa: a very feasible therapeutic possibility. Expert Opin Investig Drugs. 2009;18:569–571.
   PubMed Web of Science ®Google Scholar
• Marsh R, Steinglass JE, Gerber AJ, et al. Deficient activity in the neural systems that mediate self-regulatory control in bulimia nervosa. Arch Gen Psychiatry. 2009 Jan;66(1):51–63.
   PubMed Web of Science ®Google Scholar
• Frank GK, Reynolds JR, Shott ME, et al. Anorexia nervosa and obesity are associated with opposite brain reward response. Neuropsychopharmacology. 2012;37:2031–2046.
   PubMed Web of Science ®Google Scholar
• Keating C, Tilbrook AJ, Rossell SL, et al. Reward processing in anorexia nervosa. Neuropsychologia. 2012;50:567–575.
   PubMed Web of Science ®Google Scholar
• Davis CA, Levitan RD, Reid C, et al. Dopamine for “wanting” and opioids for “liking”: a comparison of obese adults with and without binge eating. Obesity. 2009;17:1220–1225.
   PubMed Web of Science ®Google Scholar
• Torsello A, Brambilla F, Tamiazzo L, et al. Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa. J Endocrinol Invest. 2007;30:962–976.
   PubMed Web of Science ®Google Scholar
• Gervasini G, Gamero-Villarroel C Discussing the putative role of obesity-associated genes in the etiopathogenesis of eating disorders. Pharmacogenomics. 2015;16:1287–1305
   PubMed Web of Science ®Google Scholar
• Brambilla F, Garcia CS, Fassino S, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22:197–204.
   PubMed Web of Science ®Google Scholar
• Bissada H, Tasca GA, Barber AM, et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2008;165:1281–1288.
   PubMed Web of Science ®Google Scholar
• Dold M, Aigner M, Klabunde M, et al. Second-generation antipsychotic drugs in anorexia nervosa: a meta-analysis of randomized controlled trials. Psychother Psychosom. 2015;84:110–116.
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–1696.
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519–526.
   PubMed Web of Science ®Google Scholar
• Misra M, Klibanski A Bone health in anorexia nervosa. Curr Opin Endocrinol Diabetes Obes. 2011;18:376–382.
   PubMed Web of Science ®Google Scholar
• Morton GJ, Thatcher BS, Reidelberger RD, et al. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab. 2012;302:134–144.
   PubMed Web of Science ®Google Scholar
• Blevins JE, Graham JL, Morton GJ, et al. Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 2015;308:431–438.
   PubMed Web of Science ®Google Scholar
• Brockmeyer T, Pellegrino J, Münch H, et al. Social cognition in anorexia nervosa: specific difficulties in decoding emotional but not nonemotional mental states. Int J Eat Disord. 2016;49:883–890.
   PubMed Web of Science ®Google Scholar
• Uvnäs-Moberg K, Bjökstrand E, Hillegaart V, et al. Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacology. 1999;142:95–101.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Joaquim M, Bentley J, et al. Psychopharmacological options for adult patients with anorexia nervosa: the patients’ and carers’ perspective. CNS Spectrums 2017. DOI: 10.1017/S1092852917000529. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Sanger TM Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophr Res. 1999;1(35 Suppl):13–21.
   Google Scholar
• Kluge M, Schacht A, Himmerich H, et al. Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature. Schizophr Res. 2014;152:255–260.
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee. British National Formulary 73 (BNF). 2017. Available from: https://www.bnf.org/, accessed on 01/09/2017.
   Google Scholar
• Trunko ME, Schwartz TA, Duvvuri V, et al. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. Int J Eat Disord. 2011;44:269–275.
   PubMed Web of Science ®Google Scholar
• Aragona M Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure. Eat Weight Disord. 2007 Sep;12:e54–57.
   PubMed Web of Science ®Google Scholar
• Frank GK Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa - a case series. Int J Eat Disord. 2016;49:529–533.
   PubMed Web of Science ®Google Scholar
• Marzola E, Desedime N, Giovannone C, et al. Atypical antipsychotics as augmentation therapy in anorexia nervosa. PLoS One. 2015;10:e0125569.
   PubMed Web of Science ®Google Scholar
• Grotenhermen F Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–360.
   PubMed Web of Science ®Google Scholar
• Badowski ME, Perez SE Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. Hiv Aids. 2016;8:37–45.
   Google Scholar
• Andries A, Frystyk J, Flyvbjerg A, et al. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord 2014;47:18–23.
   PubMed Web of Science ®Google Scholar
• Henderson G, Johnson JW, Ascher P Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-D-aspartate receptor. J Physiol. 1990;430:189–212.
   PubMed Web of Science ®Google Scholar
• Levinson CA, Rodebaugh TL, Fewell L, et al. D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial. J Clin Psychiatry. 2015;76:e787–793.
   PubMed Web of Science ®Google Scholar
• Myung CS, Kim BT, Choi SH, et al. Role of neuropeptide Y and proopiomelanocortin in fluoxetine-induced anorexia. Arch Pharm Res. 2005;28:716–721.
   PubMed Web of Science ®Google Scholar
• Himmerich H, Benkert O Medikamente zur behandlung von essstörungen und adipositas [Medications for the treatment of eating disorders and obesity]. In: Benkert O, Hippius H, editors. Kompendium der psychiatrischen pharmakotherapie. 11th ed. Heidelberg (Germany): Springer; 2017. p. 778–796.
   Google Scholar
• Pittenger C Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatr Ann. 2015;45:308–315.
   PubMed Web of Science ®Google Scholar
• Angehagen M, Ben-Menachem E, Rönnbäck L, et al. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res. 2003;28:333–340.
   PubMed Web of Science ®Google Scholar
• Caricilli AM, Penteado E, de Abreu LL, et al. Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice. Endocrinology. 2012;153:4401–4411.
   PubMed Web of Science ®Google Scholar
• Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, Part 1: improvement in binge and purge measures. J Clin Psychiatry. 2003;64:1335–1341.
   PubMed Web of Science ®Google Scholar
• Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, Part 2: improvement in psychiatric measures. J Clin Psychiatry. 2003;64:1449–1454.
   PubMed Web of Science ®Google Scholar
• Faris PL, Kim SW, Meller WH, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000;355:792–797.
   PubMed Web of Science ®Google Scholar
• Moffett PM, Cartwright L, Grossart EA, et al. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016;23:102–105.
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Arias AJ Targeted opioid receptor antagonists in the treatment of alcohol use disorders. CNS Drugs. 2013;27:777–787.
   PubMed Web of Science ®Google Scholar
• Jonas JM, Gold MS Treatment of antidepressant-resistant bulimia with naltrexone. Int J Psychiatry Med. 1986-1987;16:305–309.
   PubMed Web of Science ®Google Scholar
• Jonas JM, Gold MS The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone. Psychiatry Res. 1988;24:195–199.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson J, Ferreira-Cornwell MC, et al. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacol. 2016;41:1251–2160.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72:235–246.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Mori N, et al. Overview of the treatment of binge eating disorder. CNS Spectr. 2015;20:546–556.
   PubMed Web of Science ®Google Scholar
• Ikemoto S Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev. 2007;56:27–78.
   PubMed Web of Science ®Google Scholar
• Volkoff H The effects of amphetamine injections on feeding behavior and the brain expression of orexin, CART, tyrosine hydroxylase (TH) and thyrotropin releasing hormone (TRH) in goldfish (Carassius auratus). Fish Physiol Biochem. 2013;39:979–991.
   PubMed Web of Science ®Google Scholar
• Gasior M, Hudson J, Quintero J, et al. 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. J Clin Psychopharmacol. 2017;37:315–322.
   PubMed Web of Science ®Google Scholar
• Ard J, Cannon A, Lewis CE, et al. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes Obes Metab. 2016;18:430–435.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687–699.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
   PubMed Web of Science ®Google Scholar
• Jensterle M, Kravos NA, Pfeifer M, et al. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015;14:81–90.
   PubMedGoogle Scholar
• Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843–854.
   PubMed Web of Science ®Google Scholar
• Barreto-Vianna AR, Aguila MB, Mandarim-de-Lacerda CA Effects of liraglutide in hypothalamic arcuate nucleus of obese mice. Obesity (Silver Spring). 2016;24:626–633.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR–BMOD trial. Obesity (Silver Spring) 2011;19:110–120.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR–I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
   PubMed Web of Science ®Google Scholar
• Silveira RO, Zanatto V, Appolinário JC, et al. An open trial of reboxetine in obese patients with binge eating disorder. Eat Weight Disord. 2005;10:93–96.
   PubMedGoogle Scholar
• Sjödin A, Gasteyger C, Nielsen AL, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010;34:1634–1643.
   PubMed Web of Science ®Google Scholar
• Kipnes MS, Hollander P, Fujioka K, et al. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:517–531.
   PubMed Web of Science ®Google Scholar
• Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab. 2007;92:1754–1757.
   PubMed Web of Science ®Google Scholar
• Kopelman P, Groot GDE H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010;18:108–115.
   PubMed Web of Science ®Google Scholar
• Jauch-Chara K, Friedrich A, Rezmer M, et al. Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes. 2012;61:2261–2268.
   PubMed Web of Science ®Google Scholar
• Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med. 2014;126:7–18.
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21:2163–2171.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.
   PubMed Web of Science ®Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–342.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–1352.
   PubMed Web of Science ®Google Scholar
• Kyriakidis M, Caetano L, Anastasiadou N, et al. Functional hypothalamic amenorrhoea: leptin treatment, dietary intervention and counselling as alternatives to traditional practice - systematic review. Eur J Obstet Gynecol Reprod Biol. 2016;198:131–137.
   PubMed Web of Science ®Google Scholar
• Verhagen LA, Luijendijk MC, Adan RA Leptin reduces hyperactivity in an animal model for anorexia nervosa via the ventral tegmental area. Eur Neuropsychopharmacol. 2011;21:274–281.
   PubMed Web of Science ®Google Scholar
• Jukarainen S, Heinonen S, Rämö JT, et al. Obesity is associated with low NAD(+)/SIRT pathway expression in adipose tissue of BMI-discordant monozygotic twins. J Clin Endocrinol Metab. 2016;101:275–283.
   PubMed Web of Science ®Google Scholar
• Guarda AS Treatment of anorexia nervosa: insights and obstacles. Physiol Behav. 2008;94:113–120.
   PubMed Web of Science ®Google Scholar
• Petit-Zeman S, Firkins L, Scadding JW The James Lind Alliance: tackling research mismatches. Lancet. 2010; 376: 667–669.
   PubMed Web of Science ®Google Scholar
• Solmi M, Veronese N, Favaro A, et al. Inflammatory cytokines and anorexia nervosa: a meta-analysis of cross-sectional and longitudinal studies. Psychoneuroendocrinology. 2015;51:237–252.
   PubMed Web of Science ®Google Scholar
• Pisetsky DS, Trace SE, Brownley KA, et al. The expression of cytokines and chemokines in the blood of patients with severe weight loss from anorexia nervosa: an exploratory study. Cytokine. 2014;69:110–115.
   PubMed Web of Science ®Google Scholar
• Baumann A, Heitmann S, Bubendorff V, et al. Laboratory changes in anorexia nervosa. Praxis. 2010;99:661–667.
   PubMedGoogle Scholar
• Himmerich H, Sheldrick AJ TNF-alpha and ghrelin: opposite effects on immune system, metabolism and mental health. Protein Pept Lett. 2010;17:186–196.
   PubMed Web of Science ®Google Scholar
• Alam R, Abdolmaleky HM, Zhou JR Microbiome, inflammation, epigenetic alterations, and mental diseases. Am J Med Genet B Neuropsychiatr Genet. 2017;174:651–660.
   PubMed Web of Science ®Google Scholar
• Carr J, Kleiman SC, Bulik CM, et al. Can attention to the intestinal microbiota improve understanding and treatment of anorexia nervosa? Expert Rev Gastroenterol Hepatol. 2016;10:565–569.
   PubMed Web of Science ®Google Scholar